AstraZeneca And Daiichi Sankyo To Present Findings Of ENHERTU Showing Clinical Activity In Patients With HER2 Positive Metastatic Breast Cancer And Brain Metastases
AstraZeneca And Daiichi Sankyo To Present Findings Of ENHERTU Showing Clinical Activity In Patients With HER2 Positive Metastatic Breast Cancer And Brain Metastases
阿斯利康和大衛三世田井將展示ENHERTU在HER2陽性轉移性乳腺癌和腦轉移患者中顯示的臨床活性研究結果
- Daiichi Sankyo and AstraZeneca's ENHERTU achieved a 61.6% progression-free survival rate at one year in patients with active or stable brain metastases in DESTINY-Breast12
- Largest prospective trial of ENHERTU in this patient population
- Daiichi Sankyo和阿斯利康的ENHERTU在DESTINY-Breast12對於患有活動或穩定性腦轉移瘤的患者，一年生存率達到61.6%。
- ENHERTU在這一患者群體中進行的最大前瞻性試驗。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。